ZP6590 / Zealand Pharma - LARVOL DELTA

Research - strengthening our engine and expanding capabilities to fuel clinical pipeline (GlobeNewswire) - "In 2026, Zealand Pharma expects to progress its GIP analog, ZP6590, into clinical development with a first-in-human clinical trial."

First-in-human • New trial • Obesity

Zealand Pharma Announces Financial Results for the First Half of 2023 (GlobeNewswire) - "ZP6590, GIP analog. Zealand expects to complete pre-clinical activities in 2023 and advance this program into first-in-human clinical trials in the first half of 2024."

New P1 trial • Metabolic Disorders • Obesity